08:49:08 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



EnzymeBioSystems Announces Progress with an Enzyme Compound

2014-09-23 14:14 ET - News Release

CHAGRIN FALLS, Ohio, Sept. 23, 2014 /PRNewswire/ -- EnzymeBioSystems (OTCBB: ENZB) (OTCQB: ENZB), announces they have moved further along with the process of evaluating an enzyme compound which they believe has specific therapeutic value in fighting tumors. In an effort to evaluate this compound, management has had a series of meetings with various contract research organizations to enlist their expertise in performing animal studies. The research will study the use of an antitumor natural product called amooranin.  Specifically, the two areas of this study will include: 1) an exam of the in vitro cytotoxicity of amooranin against hepatocellular carcinoma cells, and 2) investigate the dose responsive antitumor actions of amooranin against chemically induced hepatic tumorgenesis in rats and dogs.

Management hopes the research will identify an enzyme compound that will lead to an Investigational New Drug application (IND) with the U.S. Federal Drug Association (FDA). It is still too early to determine if this project has any potential value for the company, and there are no assurances that the company will ever obtain an IND for this compound.

About EnzymeBioSystems

EnzymeBioSystems produces specialty enzymes and enzyme related products. We plan to use enzyme technologies to develop commercial solutions for a broad range of applications within the pharmaceutical industry. 

Included in this release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct.  The company's actual results could differ materially from those anticipated in the forward-looking statements.

Contact: Anushavan Yeranosyan
EnzymeBioSystems
Phone: +1-440-708-0012
anush@aamedsupply.com

SOURCE EnzymeBioSystems

© 2024 Canjex Publishing Ltd. All rights reserved.